Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
37970
CAS Number:
220127-57-1
Imatinib mesylate
Purity:
≥ 98% (HPLC)
Synonym(s):
Imatinib methanesulfonate
Documents
$62.59 /100MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Imatinib mesylate is a potent tyrosine kinase inhibitor primarily used in the treatment of various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This compound works by selectively inhibiting the BCR-ABL fusion protein, which is responsible for the uncontrolled proliferation of cancer cells. Its unique mechanism of action makes it a cornerstone in targeted cancer therapy, providing significant benefits over traditional chemotherapy by minimizing damage to healthy cells and reducing side effects.

In addition to its primary applications in oncology, Imatinib mesylate has shown promise in treating other conditions such as systemic mastocytosis and certain types of dermatofibrosarcoma. Researchers and healthcare professionals appreciate its effectiveness and specificity, which have led to improved patient outcomes and quality of life. With ongoing studies exploring its potential in combination therapies and new indications, Imatinib mesylate remains a critical compound in the pharmaceutical landscape, offering hope for patients with challenging diagnoses.

Synonyms
Imatinib methanesulfonate
CAS Number
220127-57-1
Purity
≥ 98% (HPLC)
Molecular Formula
C29H31N7O·CH4O3S
Molecular Weight
589.72
MDL Number
MFCD04307699
PubChem ID
123596
Appearance
White to light yellow powder to crystal
Conditions
Store at 2 - 8 °C
General Information
Synonyms
Imatinib methanesulfonate
CAS Number
220127-57-1
Purity
≥ 98% (HPLC)
Molecular Formula
C29H31N7O·CH4O3S
Molecular Weight
589.72
MDL Number
MFCD04307699
PubChem ID
123596
Appearance
White to light yellow powder to crystal
Conditions
Store at 2 - 8 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Imatinib mesylate is widely utilized in research focused on:

  • Cancer Treatment: Primarily used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), providing targeted therapy that significantly improves patient outcomes.
  • Pharmaceutical Development: Serves as a key compound in the development of new cancer therapies, allowing researchers to explore combination treatments that enhance efficacy and reduce resistance.
  • Biomarker Research: Used in studies to identify biomarkers for cancer progression, helping to tailor personalized treatment plans based on individual patient profiles.
  • Drug Resistance Studies: A valuable tool for investigating mechanisms of drug resistance in cancer cells, aiding in the development of next-generation therapies that can overcome these challenges.
  • Clinical Trials: Frequently involved in clinical trials aimed at assessing new formulations or delivery methods, contributing to advancements in cancer care and improving patient quality of life.

Citations